Johnson & Johnson (JNJ- Q3FY20) – Quarter performance affected by COVID 19.

in , on November 6, 2020

Johnson & Johnson  announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 Results Overview
– Q3FY20 Segment Performance
– Q3FY20 Developments
– FY20 Guidance
– Conclusion
– GAAP to Non GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet Items and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance 

CrispIdea Coverage 

No of Pages : 74

Release Information

  • Released
    :

    November 6, 2020

  • Last Updated
    :

    November 6, 2020